Loading clinical trials...
Loading clinical trials...
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Conditions
Interventions
Binimetinib
Palbociclib
+1 more
Locations
7
United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
Start Date
October 29, 2019
Primary Completion Date
August 23, 2021
Completion Date
July 2, 2024
Last Updated
August 22, 2024
NCT04693377
NCT04704661
NCT06696768
NCT06349642
NCT07463599
NCT04511039
Lead Sponsor
Academic and Community Cancer Research United
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions